Table 1.
Clinical characteristics of patients with pancreatic cancer (n = 65).
| Characteristics | Number of Patients (%) | |
|---|---|---|
| Age (years) | 66 (40–89) * | |
| Sex | Men | 34 (52.3%) |
| Women | 31 (47.7%) | |
| Tumor location | Head/neck | 37 (56.9%) |
| Body | 13 (20.0%) | |
| Tail | 15 (23.1%) | |
| Tumor size (cm) | 3.7 (1.9–8.7) * | |
| T classification | T1–T2 | 9 (13.8%) |
| T3–T4 | 56 (86.1%) | |
| N classification | N0 | 35 (53.8%) |
| N1 | 30 (46.2%) | |
| M classification | M0 | 53 (81.5%) |
| M1 | 12 (18.5%) | |
| Clinical TNM stage | I | 6 (9.2%) |
| II | 28 (43.1%) | |
| III | 19 (29.2%) | |
| IV | 12 (18.5%) | |
| Serum CEA (ng/mL) | 4.32 (0.56–100,000.00) * | |
| Serum CA19-9 (U/mL) | 138.5 (0.6–4628.0) * | |
| NLR | 2.26 (0.80–21.74) * | |
| PLR | 150.22 (56.96–1574.51) * | |
| PET/CT parameters | Maximum SUV of primary tumor | 7.01 (3.55–22.47) * |
| MTV of primary tumor (cm3) | 15.58 (1.91–77.37) * | |
| TLG of primary tumor (g) | 55.54 (10.11–845.87) * | |
| BM SUV | 1.74 (1.13–2.91) * | |
| BLR | 0.86 (0.49–1.86) * | |
| Treatment | Surgical resection | 37 (56.9%) |
| Concurrent chemotherapy | 13 (20.0%) | |
| Chemotherapy alone | 11 (16.9%) | |
| Radiotherapy alone | 4 (6.2%) | |
* Median value (range); BM, bone marrow; BLR, bone marrow-to-liver uptake ratio; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; MTV, metabolic tumor volume; NLR, neutrophil-to-lymphocyte ratio; PET/CT, positron emission tomography/computed tomography; PLR, platelet-to-lymphocyte ratio; SUV, standardized uptake value; TLG, total lesion glycolysis.